Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims:

1 - 8 (canceled).

9. (currently amended) A method for attenuating the progression of renal fibrosis in a subject in need thereof, exposed to an inducer of renal fibrosis, the method comprising the step of administering to the subject ~~in need thereof~~ a therapeutically effective amount of a composition comprising a compound and a pharmaceutically acceptable carrier, said compound being a member of a group having the general formula:



wherein: n=l-2

R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower

alkyl, phenyl and lower alkoxy,

R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy,

R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof; ~~and~~

~~wherein the step of administering the compound is performed before the subject exhibits a renal fibrotic condition.~~

10. (original) The method of claim 9, wherein said compound is halofuginone.

11. (original) The method of claim 9, wherein said pharmaceutically acceptable carrier enables administration of the composition orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.

12-14 (canceled).

15. (currently amended) A method for preserving renal function <u>in a subject</u> following exposure to an inducer of renal fibrosis, the method comprising the step of administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a compound having the general formula:



wherein: n=l-2

R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower

alkyl, phenyl and lower alkoxy;

R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and

R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.

16. (previously amended) The method of claim 15, wherein the compound is halofuginone.

17. (previously amended) The method of claim 15, wherein said medicament is suitable for administration orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.